Profile and investment
| Fund type | Open Ended Investment Company |
|---|---|
| Investment style (stocks) | Market Cap: Large Investment Style: Blend |
| Morningstar category | Health |
| Launch date | 30 Sep 1999 |
| Price currency | USD |
| Domicile | United States |
| Symbol | MEDX |
| Manager & start date | Peter Doyle 30 Sep 1999 Paul Abel 30 Sep 1999 |
| Pricing frequency | Daily |
|---|---|
| Total net assets | 16.66m USD As of Oct 31 2024 |
| Share class size | 16.66m USD As of Oct 31 2024 |
| Net expense ratio | 0.85% |
| Front end load | -- |
| Deferred load | -- |
| Maximum Redemption Fee | -- |
| Min. initial investment | -- |
| Min. additional investment | -- |
| Initial IRA | -- |
| Additional IRA | -- |
| Available for sale | United States |
More ▼
Top 5 holdings
| Top 5 holdings as a per cent of portfolio | |||
|---|---|---|---|
| 45.90% | 42.88% | 0.00% | 42.88% |
| Category average | % Net assets | % Short | % Long |
| Company | 1 year change | Portfolio weight | Long allocation |
|---|---|---|---|
| Eli Lilly and Co LLY:NYQ | +34.31% | 16.03% | |
| AbbVie Inc ABBV:NYQ | +40.46% | 9.00% | |
| Amgen Inc AMGN:NSQ | +19.04% | 6.18% | |
| Novartis AG 0K9E:LSE | +12.60% | 5.98% | |
| Bristol-Myers Squibb Co BMY:NYQ | +3.28% | 5.69% | |
| Per cent of portfolio in top 5 holdings: 42.88% |
Asset type
| US stock | 74.51% |
| Non-US stock | 19.56% |
| Cash | 5.93% |
| US bond | 0.00% |
| Non-US bond | 0.00% |
| Other | 0.00% |
Top 5 sectors
| Healthcare | 94.07% |
Top 5 regions
| United States | 74.51% |
| United Kingdom | 10.21% |
| Europe - ex Euro | 9.30% |
| Eurozone | 0.05% |
Sector and region weightings are calculated using only long position holdings of the portfolio.
